Literature DB >> 29625867

Balloon Aortic Valvuloplasty for Congenital Aortic Stenosis: A 14-Year Single Centre Review.

Benjamin Auld1, Lindsay Carrigan2, Cameron Ward3, Robert Justo3, Nelson Alphonso3, Ben Anderson3.   

Abstract

BACKGROUND: The approach to intervention for congenital aortic valve stenosis (AS) differs depending upon centre bias toward a primary catheter or surgical approach. We therefore investigated associations with freedom from re-intervention (FFI) in the cohort of children who underwent primary balloon aortic valvuloplasty (BAV) for congenital AS in our centre.
METHODS: All patients who underwent BAV as a primary procedure in the period between 2001 and 2015 in a single service were included. Echocardiographic parameters before and after catheterisation and procedural data was collected on all patients.
RESULTS: Sixty-four (64) patients underwent BAV as the primary intervention during the study period. Follow-up data was available for 60 of these. Balloon aortic valvuloplasty was performed at a median age of 143 days (range 2 days-18.8 years). Freedom from re-intervention was observed in 75% of patients with a median follow-up of 6.8 years and a mean follow-up of 3 years. Catheter-based peak-to-peak aortic valve gradients decreased from 58±15.9mmHg to 22.9±13.1mmHg. There was no short- or long-term mortality. FFI was predicted by aortic valve morphology (p<0.01), post-BAV mean echo gradient (p=0.03) and post-BAV regurgitation (p<0.01). No patient had re-intervention for restenosis with post-BAV mean echo gradient <30mmHg. Catheter gradients before and after BAV approached significance for predicting FFI (p=0.06 and p=0.09 respectively). Fifteen (15) patients were neonates with significantly lower aortic valve (AoV) Z-scores (mean 0.63 vs 1.76, p=0.002) and no difference in FFI (p=0.19). Annulus size, balloon/annulus ratio (within the range utilised) and pre-BAV echo findings were not predictive for re-intervention.
CONCLUSIONS: Balloon aortic valvuloplasty is an effective primary approach to congenital valvular AS with the potential of avoiding surgical intervention in the majority of patients at all ages. Freedom from re-intervention in our cohort was associated with valve morphology and the degree of stenosis and regurgitation immediately post BAV.
Copyright © 2018 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). All rights reserved.

Entities:  

Keywords:  Aortic valve disease; Balloon angioplasty; Congenital heart disease; Paediatrics; Percutaneous intervention

Mesh:

Year:  2018        PMID: 29625867     DOI: 10.1016/j.hlc.2018.02.014

Source DB:  PubMed          Journal:  Heart Lung Circ        ISSN: 1443-9506            Impact factor:   2.975


  4 in total

1.  Results of balloon and surgical valvuloplasty in congenital aortic valve stenosis: A 19-year, single-center, retrospective study.

Authors:  Kahraman Yakut; Niyazi Kürşad Tokel; Birgül Varan; İlkay Erdoğan; Murat Özkan
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2021-04-26       Impact factor: 0.332

Review 2.  Bicuspid Aortic Valve in Children and Adolescents: A Comprehensive Review.

Authors:  Gaia Spaziani; Francesca Girolami; Luigi Arcieri; Giovanni Battista Calabri; Giulio Porcedda; Chiara Di Filippo; Francesca Chiara Surace; Marco Pozzi; Silvia Favilli
Journal:  Diagnostics (Basel)       Date:  2022-07-20

3.  Balloon aortic valvuloplasty in neonates: short- and long-term effects and predictors of successful outcome.

Authors:  Filip Tyc; Michal Galeczka; Jacek Białkowski; Katarzyna Kulig; Roland Fiszer
Journal:  Postepy Kardiol Interwencyjnej       Date:  2022-08-19       Impact factor: 1.065

4.  Trajectory of Left Ventricular Remodeling in Children With Valvar Aortic Stenosis Following Balloon Aortic Valvuloplasty.

Authors:  Koyelle Papneja; Zachary M Blatman; Ian D Kawpeng; Jacqueline Wheatley; Hanne Oscé; Boning Li; Myriam Lafreniere-Roula; Chun P S Fan; Cedric Manlhiot; Lee N Benson; Luc Mertens
Journal:  Circ Cardiovasc Imaging       Date:  2022-01-18       Impact factor: 7.792

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.